Stock events for Spyre Therapeutics, Inc. (SYRE)
Several events have influenced Spyre Therapeutics' stock price. The company received positive analyst sentiment and price target raises. Spyre Therapeutics participated in multiple investor conferences in March 2026. The company outlined accelerated timelines for six proof-of-concept readouts in 2026. Spyre Therapeutics presented differentiated clinical data for its anti-IL-23 antibody SPY003 and preclinical combination therapy results at the 21st ECCO Congress in February 2026. CEO Cameron Turtle and CFO Scott Burrows sold shares in early March 2026. The stock price was impacted by broader market weakness and heightened geopolitical tensions. In October 2025, the company strengthened its balance sheet with an underwritten public offering of common stock.
Demand Seasonality affecting Spyre Therapeutics, Inc.’s stock price
As a clinical-stage biotechnology company, Spyre Therapeutics, Inc. is primarily focused on research and development and does not yet have commercialized products generating revenue. Therefore, traditional demand seasonality does not apply to Spyre Therapeutics at this stage.
Overview of Spyre Therapeutics, Inc.’s business
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for inflammatory bowel disease (IBD) and rheumatic diseases. The company uses protein engineering and biologics design platforms to create targeted molecules. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23, being developed as monotherapies and in pair-wise combinations. Key product candidates include SPY001, an anti-α4β7 antibody in Phase 2 trials for IBD; SPY002 (and SPY072), anti-TL1A antibodies in preclinical and Phase 1 development for IBD and rheumatic diseases; SPY003, a preclinical-stage anti-IL-23 program; and combination therapies like SPY120, SPY130, and SPY230.
SYRE’s Geographic footprint
Spyre Therapeutics, Inc. is headquartered in Waltham, Massachusetts, United States. The company operates a research and development facility in the United States, supporting its in-house projects and external partnerships.
SYRE Corporate Image Assessment
Spyre Therapeutics generally maintains a positive brand reputation, particularly within the investment community, driven by strong analyst support and positive sentiment surrounding its innovative product pipeline. Accelerated clinical trial timelines and positive readouts, along with a strong financial position, have positively affected its reputation. Insider selling by the CEO and CFO could be viewed with caution by some investors.
Ownership
A significant portion of Spyre Therapeutics, Inc.'s stock is owned by institutional investors, ranging from 76.84% to 103.10%. Insiders own approximately 7.48% to 32.83% of the stock, while retail investors hold a smaller percentage, approximately 0.00% to 4.40%. Major institutional owners include Fairmount Funds Management LLC, Fmr LLC, and BlackRock, Inc.
